Xeris Biopharma Holdings (XERS) Current Leases (2022 - 2026)

Xeris Biopharma Holdings' Current Leases history runs 5 years deep, the most recent figure standing at $6.3 million for Q1 2026.

• Quarterly Current Leases rose 2.52% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (up 2.52% YoY) and the FY2025 annual result came in at $6.2 million, up 2.5% from the prior year.
• Current Leases was $6.3 million for Q1 2026 at Xeris Biopharma Holdings, up from $6.2 million in the prior quarter.
• Across five years, Current Leases topped out at $6.3 million in Q1 2026 and bottomed at $1.4 million in Q1 2023.
• A 5-year average of $4.6 million and a median of $5.7 million in 2024 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases jumped 219.34% — and 2025, when it rose 2.5%.
• Xeris Biopharma Holdings' Current Leases stood at $1.6 million in 2022, then soared by 121.2% to $3.5 million in 2023, then soared by 73.96% to $6.1 million in 2024, then gained by 2.5% to $6.2 million in 2025, then grew by 0.63% to $6.3 million in 2026.
• Business Quant data shows XERS's Current Leases at $6.3 million in Q1 2026, $6.2 million in Q4 2025, and $6.2 million in Q3 2025.